Movement Alert｜Incyte Declines 5.37% in Regular Trading, Trading at $104.11

Market Focus06-15 23:04

On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.

Within the Biotechnology sector where Incyte belongs, the overall sector performance was mixed. Among individual stocks, Regentis Biomaterials Ltd. up 165.35%, AbbVie down 2.6%, Amgen up 0.66%, Gilead Sciences up 0.01%, Regeneron Pharmaceuticals down 0.03%.

Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity. Key products include JAKAFI (ruxolitinib), MONJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab), and OPZELURA cream.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1168018671?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 23:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168018671","market":"us","top_or_hot":-1,"title":"Movement Alert｜Incyte Declines 5.37% in Regular Trading, Trading at $104.11","media":"Market Focus","content":"<p><p>On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.</p><p>Within the Biotechnology sector where Incyte belongs, the overall sector performance was mixed. Among individual stocks, Regentis Biomaterials Ltd. up 165.35%, AbbVie down 2.6%, Amgen up 0.66%, Gilead Sciences up 0.01%, Regeneron Pharmaceuticals down 0.03%.</p><p>Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity. Key products include JAKAFI (ruxolitinib), MONJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab), and OPZELURA cream.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Incyte Declines 5.37% in Regular Trading, Trading at $104.11</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Incyte Declines 5.37% in Regular Trading, Trading at $104.11\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-15 23:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.</p><p>Within the Biotechnology sector where Incyte belongs, the overall sector performance was mixed. Among individual stocks, Regentis Biomaterials Ltd. up 165.35%, AbbVie down 2.6%, Amgen up 0.66%, Gilead Sciences up 0.01%, Regeneron Pharmaceuticals down 0.03%.</p><p>Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity. Key products include JAKAFI (ruxolitinib), MONJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab), and OPZELURA cream.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INCY","symbol_name":"因塞特医疗","start_time":0,"source_url":"","article_id":"1168018671","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168018671","pubTimestamp":1781535878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.Within the Biotechnology sector where Incyte belongs, the overall sector performance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INCY":"因塞特医疗"},"translate_title":"走势提示|Incyte常规交易下跌5.37%，报104.11美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INCY":1},"content_text":"On June 15, Incyte declined 5.37% in regular trading, trading at $104.11/share, with Turnover of $64.25 million.Within the Biotechnology sector where Incyte belongs, the overall sector performance was mixed. Among individual stocks, Regentis Biomaterials Ltd. up 165.35%, AbbVie down 2.6%, Amgen up 0.66%, Gilead Sciences up 0.01%, Regeneron Pharmaceuticals down 0.03%.Incyte Corporation is a global biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity. Key products include JAKAFI (ruxolitinib), MONJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), ZYNYZ (retifanlimab), and OPZELURA cream.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1168018671","isCrawlerRequest":true}